Q-omics provides the consensus-scored HACE1 profile across patient tissues and cancer cell-line models. HACE1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, HACE1 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, HACE1 RNA expression shows 21,105 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, KICH, and ACC as cancer lineages where HACE1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HACE1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HACE1 survival associations across molecular data types. HACE1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HACE1 RNA expression–survival associations across cancer types. High HACE1 expression shows unfavorable associations in LIHC, KIRP and KICH, but favorable associations in KIRC, SCLC and UCS. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for HACE1 RNA expression.
This table summarizes HACE1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for HACE1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HACE1 shows lower tumor expression in KICH, THCA, KIRC and KIRP and higher tumor expression in LIHC and CHOL. The KICH box plot shows higher HACE1 RNA expression in normal versus tumor tissue (log2 FC = −1.774, t-test p < 0.001).
This table shows molecular features associated with HACE1 in patient tissues and cancer cell lines. In patient samples, HACE1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, HACE1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
